These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Dickson DW; Fujishiro H; DelleDonne A; Menke J; Ahmed Z; Klos KJ; Josephs KA; Frigerio R; Burnett M; Parisi JE; Ahlskog JE Acta Neuropathol; 2008 Apr; 115(4):437-44. PubMed ID: 18264713 [TBL] [Abstract][Full Text] [Related]
4. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients. Doorn KJ; Moors T; Drukarch B; van de Berg WDj; Lucassen PJ; van Dam AM Acta Neuropathol Commun; 2014 Aug; 2():90. PubMed ID: 25099483 [TBL] [Abstract][Full Text] [Related]
5. Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy. Desai Bradaric B; Patel A; Schneider JA; Carvey PM; Hendey B J Neural Transm (Vienna); 2012 Jan; 119(1):59-71. PubMed ID: 21748523 [TBL] [Abstract][Full Text] [Related]
6. Parkinson disease and incidental Lewy body disease: Just a question of time? Iacono D; Geraci-Erck M; Rabin ML; Adler CH; Serrano G; Beach TG; Kurlan R Neurology; 2015 Nov; 85(19):1670-9. PubMed ID: 26468408 [TBL] [Abstract][Full Text] [Related]
7. Modeling nigrostriatal degeneration in organotypic cultures, a new ex vivo model of Parkinson's disease. Daviaud N; Garbayo E; Lautram N; Franconi F; Lemaire L; Perez-Pinzon M; Montero-Menei CN Neuroscience; 2014 Jan; 256():10-22. PubMed ID: 24161279 [TBL] [Abstract][Full Text] [Related]
8. Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases. Walker DG; Lue LF; Serrano G; Adler CH; Caviness JN; Sue LI; Beach TG Front Neurosci; 2015; 9():507. PubMed ID: 26834537 [TBL] [Abstract][Full Text] [Related]
9. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies]. Orimo S Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627 [TBL] [Abstract][Full Text] [Related]
10. [Multi-Organ Distribution of Alpha-Synuclein Pathology in Dementia with Lewy Bodies]. Wakabayashi K; Miki Y Brain Nerve; 2018 May; 70(5):489-500. PubMed ID: 29760287 [TBL] [Abstract][Full Text] [Related]
11. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Milber JM; Noorigian JV; Morley JF; Petrovitch H; White L; Ross GW; Duda JE Neurology; 2012 Dec; 79(24):2307-14. PubMed ID: 23152586 [TBL] [Abstract][Full Text] [Related]
15. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control. Koziorowski D; Friedman A; Arosio P; Santambrogio P; Dziewulska D Parkinsonism Relat Disord; 2007 May; 13(4):214-8. PubMed ID: 17275395 [TBL] [Abstract][Full Text] [Related]
16. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
18. Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. Frigerio R; Fujishiro H; Maraganore DM; Klos KJ; DelleDonne A; Heckman MG; Crook JE; Josephs KA; Parisi JE; Boeve BF; Dickson DW; Ahlskog JE Arch Neurol; 2009 Sep; 66(9):1114-9. PubMed ID: 19752300 [TBL] [Abstract][Full Text] [Related]
19. TIGAR inclusion pathology is specific for Lewy body diseases. López KLR; Simpson JE; Watson LC; Mortiboys H; Hautbergue GM; Bandmann O; Highley JR Brain Res; 2019 Mar; 1706():218-223. PubMed ID: 30267647 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling. Kasanga EA; Han Y; Navarrete W; McManus R; Shifflet MK; Parry C; Barahona A; Manfredsson FP; Nejtek VA; Richardson JR; Salvatore MF Exp Neurol; 2023 Aug; 366():114435. PubMed ID: 37178997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]